{
    "clinical_study": {
        "@rank": "10099", 
        "acronym": "ELDOR", 
        "arm_group": [
            {
                "arm_group_label": "Levosimendan", 
                "arm_group_type": "Active Comparator", 
                "description": "Levosimendan administration is initiated with a loading dose of 12\u03bcg/kg given over 10 min followed by a continuous infusion of 0.1 \u03bcg/kg/min for 65 min."
            }, 
            {
                "arm_group_label": "Dobutamine", 
                "arm_group_type": "Active Comparator", 
                "description": "Dobutamine is given as a continuous infusion without a bolus dose. The infusion rate is started at 5.0 \u03bcg/kg/min for 10 minutes, and thereafter increased to 7,5 \u03bcg/kg/min for 65 min."
            }
        ], 
        "brief_summary": {
            "textblock": "Although inotropes have a favorable effect on central hemodynamics in patients with heart\n      failure, their effect on renal hemodynamics is incompletely defined. The purpose of this\n      study is to evaluate the efficacy of a 75 min intravenous infusion of levosimendan compared\n      to a 75 min infusion of dobutamine on renal hemodynamics and function in patients with\n      chronic heart failure and signs of cardiorenal syndrome. The investigators hypothesis is\n      that patients treated with levosimendan will show greater increases in renal blood flow and\n      glomerular filtration rate (GFR) than those treated with dobutamine."
        }, 
        "brief_title": "Levosimendan Versus Dobutamine for Renal Function in Heart Failure", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Cardiorenal Syndrome", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written, signed and dated informed consent\n\n          -  Male and Female subjects \u226518 years of age\n\n          -  Chronic congestive heart failure scheduled for right sided cardiac catheterization\n\n          -  Left ventricular ejection fraction \u2264 40% determined by echocardiography\n\n          -  Elevation of N Terminal-proBNP \u2265 500 ng/L\n\n          -  Cardiorenal syndrome (30ml/min \u2264 estimated GFR \u2264 80 ml/min (MDRD)\n\n        Exclusion Criteria:\n\n          -  Acute heart failure, untreated\n\n          -  Systolic blood pressure < 80 mmHg\n\n          -  Tachycardia above 100 bpm\n\n          -  Angina Canadian Cardiovascular Society (CCS) class III or higher\n\n          -  Aortic stenosis\n\n          -  Hypertrophic cardiomyopathy\n\n          -  Restrictive cardiomyopathy\n\n          -  The presence of kidney disease diagnosed before heart failure\n\n          -  Administration of radiographic contrast < 1 week\n\n          -  Radiographic contrast allergy\n\n          -  In the Investigator's opinion, the patient has a clinically significant disease that\n             could be adversely      affected by study participation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02133105", 
            "org_study_id": "2013-000986-36", 
            "secondary_id": "2013-000986-36"
        }, 
        "intervention": [
            {
                "arm_group_label": "Levosimendan", 
                "intervention_name": "Levosimendan", 
                "intervention_type": "Drug", 
                "other_name": "Simdax"
            }, 
            {
                "arm_group_label": "Dobutamine", 
                "intervention_name": "Dobutamine", 
                "intervention_type": "Drug", 
                "other_name": "Dobutrex"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Simendan", 
                "Dobutamine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Heart failure", 
            "Renal failure", 
            "Inotropic drugs", 
            "Levosimendan", 
            "Dobutamine"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gothenburg", 
                    "country": "Sweden", 
                    "zip": "41345"
                }, 
                "name": "Sahlgrenska University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy of Intravenous Levosimendan Compared With Dobutamine on Renal Hemodynamics and Function in Chronic Heart Failure", 
        "overall_official": {
            "affiliation": "Sahlgrenska University Hospital, Department of Cardiology", 
            "last_name": "Kristjan Karason, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Sweden: Medicinal Products Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Para-aminohippuric acid (PAH) infusion clearance", 
                "measure": "Change in renal blood flow", 
                "safety_issue": "No", 
                "time_frame": "75 min minus baseline"
            }, 
            {
                "description": "Chrome-ethylenediaminetetraacetic acid (EDTA) infusion clearance", 
                "measure": "Change in glomerular filtration rate", 
                "safety_issue": "No", 
                "time_frame": "75 min minus baseline"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02133105"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Renal blood flow divided by the difference between renal arterial pressure and renal venous pressure", 
                "measure": "Change in renal vascular resistance", 
                "safety_issue": "No", 
                "time_frame": "75 min minus baseline"
            }, 
            {
                "description": "Right atrial pressure, mean pulmonary arterial pressure, pulmonary capillary wedge pressure, mean arterial pressure, cardiac output, pulmonary vascular resistance and systemic vascular resistance measured with a pulmonary artery thermodilution catheter.", 
                "measure": "Change in central hemodynamics", 
                "safety_issue": "No", 
                "time_frame": "75 min minus baseline"
            }, 
            {
                "description": "Oxygen consumption: Renal blood flow multiplied by arterial-renal venous oxygen difference.\nOxygen extraction: Ratio of renal oxygen consumption to renal oxygen delivery", 
                "measure": "Change in renal oxygen consumption and oxygen extraction", 
                "safety_issue": "No", 
                "time_frame": "75 min minus baseline"
            }, 
            {
                "description": "Ratio of glomerular filtration rate to renal plasma flow", 
                "measure": "Change in filtration fraction", 
                "safety_issue": "No", 
                "time_frame": "75 min minus baseline"
            }
        ], 
        "source": "G\u00f6teborg University", 
        "sponsors": {
            "collaborator": {
                "agency": "Sahlgrenska University Hospital, Sweden", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "G\u00f6teborg University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}